A Cobb

C Harrod

G Chene

J Banchereau

K Palucka

L Sloan

null null

Y Levy

English

PubMed

Banchereau, Jacques

Harrod, Carson

Cobb, Amanda

Chêne, Geneviève

Sloan, Louis

Palucka, Karolina

Levy, Yves

HAL-Inserm

P18-11. DALIA: dendritic cell and lipopeptide-induced immunity against AIDS: a phase I trial

Springer - Publisher Connector

BioMed Central
Page 1 of 1
(page number not for citation purposes)
Retrovirology
Open AccessPoster presentation
P18-11. DALIA: dendritic cell and lipopeptide-induced immunity 
against AIDS: a phase I trial
J Banchereau1, C Harrod*1, A Cobb1, G Chene2, L Sloan3, K Palucka1, Y Levy4 
and DALIA Team1
Address: 1Baylor Institute for Immunology Research (INSERM Unit 899), Dallas, TX, USA, 2Institut de Santé Publique, d'Epidémiologie et de 
Developpement, Bordeaux, France, 3North Texas Infectious Diseases Clinic, Dallas, TX, USA and 4Agence Nationale de Recherche sur le Sida et les 
hépatites virales, Paris, France
* Corresponding author    
Background
The advent of highly active antiretroviral therapies
(HAART) changed the course of human immunodefi-
ciency virus (HIV) infection. However, HAART induces a
large range of toxicities, highlighting the need for novel
therapeutic strategies, such as an effective therapeutic vac-
cine. Vaccines act via dendritic cells (DCs), which induce,
regulate and maintain immune responses.
Methods
In our view, three parameters are critical for the genera-
tion of potent ex vivo-generated DC vaccines for HIV
patients: 1) antigen; 2) DC type; and 3) activation signal.
With this in mind, we designed a clinical trial (IRB#008-
017; BB-IND #13748) to test the safety and immune effi-
cacy of a therapeutic HIV vaccine consisting of autologous
DCs generated ex vivo from monocytes cultured with GM-
CSF/IFN-alpha and loaded with five lipidated HIV anti-
gens (LIPO5). Our trial exploits a combination of: 1) HIV-
derived lipopeptides that cover nef, gag and pol epitopes
– binding to >90% of HLA molecules and permitting pres-
entation of T cell epitopes and generation of humoral
immunity; 2) Interferon (IFN)-DCs, which demonstrate
powerful priming functions in vitro; and 3) LPS activation,
which enhances priming by IFN-DCs. Such a vaccine is
expected to induce strong and diverse HIV-specific
immune responses.
Results
This phase I clinical trial in 19 asymptomatic HIV-infected
patients with undetectable viral load while treated with
HAART will test the safety of DC vaccination and of ana-
lytical treatment interruption (ATI). Patients receive four
monthly DC vaccinations in conjunction with antiretrovi-
ral therapy. Twelve weeks after the fourth vaccine, patients
who meet the pre-specified criteria will stop HAART. ATI
will last for up to six months.
Conclusion
The primary end point of the trial is safety. Secondary end-
points are immune, including: strength of HIV-specific
CD4/CD8 responses, proportion of responders, and
breadth of T cell responses. Immune responses will be
assessed using IFN-gamma ELISPOT, polychromatic flow
cytometry, EPIMAX and transcriptional profiling.
from AIDS Vaccine 2009
Paris, France. 19–22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P320 doi:10.1186/1742-4690-6-S3-P320
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P320
© 2009 Banchereau et al; licensee BioMed Central Ltd. 


Palucka K

Sloan L

Chene G

Cobb A

Harrod C

Banchereau J

Levy Y

Directory of Open Access Journals

Retrovirology

HAL: Hyper Article en Ligne

Crossref

https://inserm.hal.science/inserm-00663917v1/file/1742-4690-6-S3-P320.pdf

P18-11. DALIA: dendritic cell and lipopeptide-induced immunity against AIDS: a phase I trial

Abstract

Similar works

Full text

Available Versions

HAL-Inserm

Springer - Publisher Connector

Springer - Publisher Connector

Directory of Open Access Journals

HAL: Hyper Article en Ligne

Crossref